Actineer, a joint venture between ITM and Canadian Nuclear Laboratories (CNL) has appointed Joseph Oliverio as president and Chief Executive Officer (CEO).
Joseph Oliverio.Business Wire
Oliverio’s work will focus on leading Actineer’s global expansion in actinium-225 (Ac-225) production as demand for the alpha-emitter continues to rise.
Oliverio joins Actineer with over 30 years of leadership experience across the nuclear medicine, medical device, and radiopharmaceutical industries, including roles at Ionetix, Imagin Molecular, and Positron.